Burning mouth syndrome responsive to pramipexol

Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuginski-Barbosa, J., Rodrigues, G. G. R., Bigal, M. E., Speciali, J. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2008
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476177/
https://www.ncbi.nlm.nih.gov/pubmed/18219443
http://dx.doi.org/10.1007/s10194-008-0003-4
_version_ 1782247066688290816
author Stuginski-Barbosa, J.
Rodrigues, G. G. R.
Bigal, M. E.
Speciali, J. G.
author_facet Stuginski-Barbosa, J.
Rodrigues, G. G. R.
Bigal, M. E.
Speciali, J. G.
author_sort Stuginski-Barbosa, J.
collection PubMed
description Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings.
format Online
Article
Text
id pubmed-3476177
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-34761772012-11-29 Burning mouth syndrome responsive to pramipexol Stuginski-Barbosa, J. Rodrigues, G. G. R. Bigal, M. E. Speciali, J. G. J Headache Pain Brief Report Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings. Springer Milan 2008-01-25 2008-02 /pmc/articles/PMC3476177/ /pubmed/18219443 http://dx.doi.org/10.1007/s10194-008-0003-4 Text en © Springer-Verlag 2008
spellingShingle Brief Report
Stuginski-Barbosa, J.
Rodrigues, G. G. R.
Bigal, M. E.
Speciali, J. G.
Burning mouth syndrome responsive to pramipexol
title Burning mouth syndrome responsive to pramipexol
title_full Burning mouth syndrome responsive to pramipexol
title_fullStr Burning mouth syndrome responsive to pramipexol
title_full_unstemmed Burning mouth syndrome responsive to pramipexol
title_short Burning mouth syndrome responsive to pramipexol
title_sort burning mouth syndrome responsive to pramipexol
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476177/
https://www.ncbi.nlm.nih.gov/pubmed/18219443
http://dx.doi.org/10.1007/s10194-008-0003-4
work_keys_str_mv AT stuginskibarbosaj burningmouthsyndromeresponsivetopramipexol
AT rodriguesggr burningmouthsyndromeresponsivetopramipexol
AT bigalme burningmouthsyndromeresponsivetopramipexol
AT specialijg burningmouthsyndromeresponsivetopramipexol

Ejemplares similares